A new therapy developed by researchers at the University of Toronto may bring us one step closer to effectively killing deadly drug-resistant superbugs. “The threat posed by pathogens that are increasingly becoming resistant to all known antibiotics is an alarming and pressing health care problem,” says Ruby Sullan, assistant professor in the department of physical...
Combination therapy reduces tumor size, dramatically improves survival in mice NORTHWESTERN UNIVERSITY CHICAGO — When breast cancer spreads to the brain, the prognosis is grim. Patients only have about six months to live. Women with HER2-positive breast cancer tend to develop brain metastases in up to 55% of cases. Chemotherapy drugs targeting breast cancer cells...
Dr. Abhishek Jain, assistant professor in the Department of Biomedical Engineering and the Department of Medical Physiology in the College of Medicine, collaborated with researchers from the Departments of Gynecologic Oncology and Cancer Biology at MD Anderson Cancer Center to gain a better understanding of the interaction among ovarian cancer tumors, blood vessels and platelets....
by University of Chicago Medical Center Results from an international clinical trial found that men with advanced prostate cancer who have mutated BRCA1/BRCA2 genes can be treated successfully with a targeted therapy known as rucaparib, resulting in recent FDA approval. Prostate cancer is the most common cancer and the second leading cause of cancer death...
by Ana María Rodríguez, Ph.D., Baylor College of Medicine Scanning electron microscopy image of a human lymphocyte. Credit: National Cancer Institute Personalized cancer treatments are no longer just options of the future. In the past few years, researchers have made significant progress in ‘teaching’ the body’s immune T cells to recognize and kill specific cancer...
by German Cancer Research Center The metabolic enzyme IL4I1 (Interleukin-4-Induced-1) promotes the spread of tumor cells and suppresses the immune system. This was discovered by scientists at the German Cancer Research Center (DKFZ) and the Berlin Institute of Health (BIH). The enzyme that activates the dioxin receptor is produced in large quantities by tumor cells....
SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE ANINDYA BAGCHI, PH.D., ASSOCIATE PROFESSOR IN THE TUMOR INITIATION AND MAINTENANCE PROGRAM AT SANFORD BURNHAM PREBYS. view more CREDIT: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE Scientists at Sanford Burnham Prebys Medical Discovery Institute have uncovered a novel drug target, a protein called PPP1R1B, that stops the deadly spread of...
OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER COLUMBUS, Ohio – The findings of a new study led by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) could refine an important set of prognostic and treatment recommendations for younger adult patients...
by University of Alabama at Birmingham Precision medicine in cancer treatment uses genetic changes in the cancer cells to select the best therapies for individual patients. Now researchers led by James Bibb, Ph.D., professor of surgery at the University of Alabama at Birmingham, suggest using a broader lens of post-translational modification analysis to identify new...
by University of California – San Diego With advances in genome sequencing, cancer treatments have increasingly sought to leverage the idea of “synthetic lethality,” exploiting cancer-specific genetic defects to identify targets that are uniquely essential to the survival of cancer cells. Synthetic lethality results when non-lethal mutations in different genes become deadly when combined in...
